

K072592

**TAB 5**

**510(K) SUMMARY**

**Date of Submission** 12 September 2007

**Official Contact** Zita A. Yurko  
Director, Regulatory Affairs  
Respironics, Inc.  
1001 Murry Ridge Lane  
Murrysville, PA 15668  
[Zita.yurko@respironics.com](mailto:Zita.yurko@respironics.com)  
  
724-387-4120 t  
724-882-4120 c  
724-387-4216 f

**Classification Reference** 21 CFR 868.5905

**Product Code** BZD – Ventilator, Non-Continuous (respirator)

**Common/Usual Name** Ventilator, continuous, non-life supporting

**Proprietary Name** Respironics Performax Total Face Mask

**Predicate Device(s)** Respironics Total Face Mask (K992969) - BZD

**Reason for submission** modified device

DEC 19 2007

**Substantial Equivalence**

The Respironics Performax Total Face Mask has the following similarities to the previously cleared predicate device:

- Same intended use.
- Same operating principle.
- Same technology.
- Same manufacturing process.

This premarket notification submission demonstrates that the Performax Total Face Mask is substantially equivalent to the design of the Respironics Total Face Mask (K992969). Design modifications have been made to the Total Face Mask for this submission. These modifications are described here in. Based on the testing performed, none of the design modification affect the safety or effectiveness of the device.

The following changes have been made:

- The change in the face plate design to contour the face
- The change in the sealing cushion design
- The change in the entrainment valve design to replace the flapper with magnet design with a silicone flapper design
- The addition of the claim for multi-patient use to be included.

### **Intended Use**

The Performax Total Face Mask is intended to provide an interface for application of CPAP or BiPAP therapy to patients. The mask is for multi-patient reuse on adult patients in the home or hospital/institutional environment.

### **Device Description**

The Respironics Performax Total Face Mask consists of a polycarbonate faceplate with silicon cushion seal for the face. An integrated entrainment valve is provided for exhalation. The integrated entrainment valve elbow is polycarbonate with a silicone flapper. The function of the entrainment valve is unchanged from K992969. The mask when used with the integrated entrainment valve has two integrated exhalation features, which includes the one port on the faceplate and an exhalation site on the elbow. A separate exhalation device is not required for the integrated entrainment valve design. Similar to the device predicate, Total Face Mask, the mask faceplate contains headgear hooks upon which the premium headgear is attached. The mask is available in two sizes – small and large.

The Respironics Performax Total Face Mask is intended for use with a patient circuit that is used to connect the device to the patient interface device (mask). A typical patient circuit consists of a six-foot disposable or reusable smooth lumen 22mm tubing, a method of venting exhaled gases.

*(End of Tab.)*



DEC 19 2007

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Zita Yurko  
Director, Regulatory Affairs  
Respironics Incorporated, Sleep & Home Respiratory Group  
1001 Murry Ridge Lane  
Murrysville, Pennsylvania 15668

Re: K072592  
Trade/Device Name: Respironics Performax Total Face Mask  
Regulation Number: 868.5905  
Regulation Name: Noncontinuous Ventilator (IPPB)  
Regulatory Class: II  
Product Code: BZD  
Dated: November 21, 2007  
Received: November 23, 2007

Dear Ms. Yurko:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,  
Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and  
Radiological Health

Enclosure

### Indications for Use

510(k) Number (if known): \_\_\_\_\_

Device Name: Respironics Performax Total Face Mask


The Performax Total Face Mask is intended to provide an interface for application of Respironics CPAP or BiPAP therapy to patients. For multi-patient reuse in the home or hospital/institutional environment. The mask is to be used on patients (>66 lbs/30 kg) for whom CPAP or BiPAP therapy has been prescribed using a Respironics CPAP or BiPAP System. An exhalation port is built into this mask so that a separate exhalation port is not required. This mask is latex free and Di(2-ethylhexyl)phthalate free.

Prescription Use  X  AND/OR Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



*[Faint, illegible text]*

K072592